Yu Shi-Yuan, Ge Zeng-Zheng, Xiang Jun, Gao Yan-Xia, Lu Xin, Walline Joseph Harold, Qin Mu-Bing, Zhu Hua-Dong, Li Yi
Emergency Department, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China.
General Medicine Department of Jingnan Medical Center, General Hospital of PLA, Beijing 100039, China.
World J Emerg Med. 2022;13(5):367-372. doi: 10.5847/wjem.j.1920-8642.2022.072.
Sepsis is a common cause of death in emergency departments and sepsis-associated encephalopathy (SAE) is a major complication. Rosuvastatin may play a neuroprotective role due to its protective effects on the vascular endothelium and its anti-inflammatory functions. Our study aimed to explore the potential protective function of rosuvastatin against SAE.
Sepsis patients without any neurological dysfunction on admission were prospectively enrolled in the "Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome" study (SAILS trial, ClinicalTrials.gov number: NCT00979121). Patients were divided into rosuvastatin and placebo groups. This is a secondary analysis of the SAILS dataset. Baseline characteristics, therapy outcomes, and adverse drug events were compared between groups.
A total of 86 patients were eligible for our study. Of these patients, 51 were treated with rosuvastatin. There were significantly fewer cases of SAE in the rosuvastatin group than in the placebo group (32.1% vs. 57.1%, P=0.028). However, creatine kinase levels were significantly higher in the rosuvastatin group than in the placebo group (233 [22-689] U/L vs. 79 [12-206] U/L, P=0.034).
Rosuvastatin appears to have a protective role against SAE but may result in a higher incidence of adverse events.
脓毒症是急诊科常见的死亡原因，脓毒症相关脑病（SAE）是主要并发症。瑞舒伐他汀因其对血管内皮的保护作用和抗炎功能可能发挥神经保护作用。我们的研究旨在探讨瑞舒伐他汀对SAE的潜在保护作用。
前瞻性纳入“瑞舒伐他汀治疗脓毒症相关急性呼吸窘迫综合征”研究（SAILS试验，ClinicalTrials.gov编号：NCT00979121）中入院时无任何神经功能障碍的脓毒症患者。患者分为瑞舒伐他汀组和安慰剂组。这是对SAILS数据集的二次分析。比较两组的基线特征、治疗结果和药物不良事件。
共有86例患者符合我们的研究条件。其中，51例接受瑞舒伐他汀治疗。瑞舒伐他汀组的SAE病例明显少于安慰剂组（32.1%对57.1%，P = 0.028）。然而，瑞舒伐他汀组的肌酸激酶水平明显高于安慰剂组（233 [22 - 689] U/L对79 [12 - 206] U/L，P = 0.034）。
瑞舒伐他汀似乎对SAE有保护作用，但可能导致不良事件发生率较高。
